EndoBarrier™ Implantation Rapidly Improves Insulin Sensitivity in Obese Individuals with Type 2 Diabetes Mellitus

Biomolecules. 2021 Apr 14;11(4):574. doi: 10.3390/biom11040574.

Abstract

The EndoBarrier™ medical device is a duodenal-jejunal bypass liner designed to mimic the effects of gastric bypass surgery to induce weight loss and glycaemic improvement. In this study, 10 participants with type 2 diabetes mellitus (T2DM), a mean body mass index (BMI) of 43.3 ± 5.0 (kg/m2) and a mean glycated haemoglobin A1c (HbA1c) of 60.6 ± 8.6 mmol/mol were examined at baseline (before implantation of EndoBarrier™), 4 weeks after implantation, at 36 weeks (right before explantation) and 24 weeks after the removal of the device to explore the short and long-term effects on glucose metabolism. Besides a significant reduction in body weight and fat mass, EndoBarrier™ treatment significantly improved insulin sensitivity during Botnia clamp investigations after four weeks of implantation. The beneficial effects decreased over time but remained significant 24 weeks after removal of the device.

Keywords: Botnia clamp; EndoBarrier™; duodenal-jejunal bypass liner; obesity; type 2 diabetes mellitus.

Publication types

  • Clinical Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiposity
  • Adult
  • Bariatric Surgery / instrumentation
  • Bariatric Surgery / methods*
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / surgery*
  • Female
  • Glycated Hemoglobin / metabolism
  • Humans
  • Insulin Resistance*
  • Jejunum / surgery
  • Male
  • Middle Aged
  • Obesity / complications
  • Obesity / surgery*
  • Prostheses and Implants*
  • Weight Loss

Substances

  • Blood Glucose
  • Glycated Hemoglobin A